Breaking News

Covis Acquires Rights to Sanofi Drugs

April 5, 2013

Will promote five products in the U.S.

Covis Pharma Sarl has entered an agreement with sanofi-aventis U.S. and its affiliates to acquire full commercial rights to Nilandron, Plaquenil, Rilutek, Uroxatral, and Kayexalate in the U.S. The products are for prostate cancer, anti-malarial, ALS, Benign Prostatic Hyperplasia (BPH), and dangerously high levels of potassium in the blood, respectively. Together these products had sales of $114.6 million in the U.S. in 2012. Sanofi will retain the existing rights for these products outside the U.S.
Covis Pharma will promote these products through its U.S. distributor, Covis Pharmaceuticals, Inc. Sanofi will manufacture and supply the products for Covis Pharma.
"We are very pleased to announce the addition of these products to our existing portfolio," said Jack Davis, chief executive officer of Covis Pharma. "Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need."
blog comments powered by Disqus
  • 2016 Outsourcing Survey

    2016 Outsourcing Survey

    Tim Wright, Editor||May 5, 2016
    Herein are the results of our 2016 Annual Outsourcing Survey

  • Process Development Trends

    Process Development Trends

    Steve Haswell, 3M Drug Delivery Systems||May 5, 2016
    An approach to process development of pMDIs using cold fill and pressure fill technology

  • Pharma IT Trends

    Pharma IT Trends

    Christian Fortunel, LZ Lifescience ||May 5, 2016
    The challenge of implementing MES technology with increased regulation